List of Excipients in API zidesamtinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing zidesamtinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Nuvalent Inc | JIDEYTRO | zidesamtinib | 85001-101 | FERRIC OXIDE RED | |
| Nuvalent Inc | JIDEYTRO | zidesamtinib | 85001-101 | FERRIC OXIDE YELLOW | |
| Nuvalent Inc | JIDEYTRO | zidesamtinib | 85001-101 | HYDROXYPROPYL CELLULOSE | |
| Nuvalent Inc | JIDEYTRO | zidesamtinib | 85001-101 | HYPROMELLOSE 2910 | |
| Nuvalent Inc | JIDEYTRO | zidesamtinib | 85001-101 | MAGNESIUM STEARATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for zidesamtinib
Excipient focus: FERRIC OXIDE RED
zidesamtinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
zidesamtinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
zidesamtinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
zidesamtinib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
zidesamtinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
zidesamtinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICIFIED MICROCRYSTALLINE CELLULOSE
zidesamtinib drug variants containing SILICIFIED MICROCRYSTALLINE CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing SILICIFIED MICROCRYSTALLINE CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A
zidesamtinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
zidesamtinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
zidesamtinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Nuvalent Inc | zidesamtinib | 85001-101 |
| >Company | >Ingredient | >NDC |
zidesamtinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch